HIVCHigh Inferior Vena Cava
References in periodicals archive ?
The Company anticipates resuming trading under the symbol: (OTC:BB) HIVC in the near future.
Pursuant to the merger with LifePlan, a company reporting under the Securities Exchange Act of 1934, HIVC has elected successor issuer status as provided for under the Exchange Act.
HIVC has developed its new and very unique approach to the AIDS problem through the creation of a unique intracellular vaccine based on technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines.